[HTML][HTML] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …
[HTML][HTML] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
LJ Rupp, K Schumann, KT Roybal, RE Gate… - Scientific …, 2017 - ncbi.nlm.nih.gov
Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …
[PDF][PDF] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
LJ Rupp, K Schumann, KT Roybal, RE Gate, CJ Ye - d-nb.info
Results PD-L1 expression on tumor cells impairs CAR T cell function in vitro. While the PD-
1/PD-L1 pathway has been shown to modulate endogenous TCR signaling and …
1/PD-L1 pathway has been shown to modulate endogenous TCR signaling and …
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
LJ Rupp, K Schumann, KT Roybal, RE Gate, CJ Ye… - Scientific Reports, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Immunotherapies with chimeric antigen
receptor (CAR) T cells and checkpoint inhibitors (including antibodies that antagonize …
receptor (CAR) T cells and checkpoint inhibitors (including antibodies that antagonize …
[PDF][PDF] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
LJ Rupp, K Schumann, KT Roybal, RE Gate, CJ Ye - ucsf-cmp.github.io
Results PD-L1 expression on tumor cells impairs CAR T cell function in vitro. While the PD-
1/PD-L1 pathway has been shown to modulate endogenous TCR signaling and …
1/PD-L1 pathway has been shown to modulate endogenous TCR signaling and …
[PDF][PDF] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
LJ Rupp, K Schumann, KT Roybal, RE Gate, CJ Ye - scienceopen.com
Results PD-L1 expression on tumor cells impairs CAR T cell function in vitro. While the PD-
1/PD-L1 pathway has been shown to modulate endogenous TCR signaling and …
1/PD-L1 pathway has been shown to modulate endogenous TCR signaling and …
[PDF][PDF] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
LJ Rupp, K Schumann, KT Roybal, RE Gate, CJ Ye - limlab.ucsf.edu
Results PD-L1 expression on tumor cells impairs CAR T cell function in vitro. While the PD-
1/PD-L1 pathway has been shown to modulate endogenous TCR signaling and …
1/PD-L1 pathway has been shown to modulate endogenous TCR signaling and …
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
LJ Rupp, K Schumann, KT Roybal, RE Gate… - Scientific …, 2017 - ui.adsabs.harvard.edu
Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
LJ Rupp, K Schumann, KT Roybal, RE Gate… - Scientific …, 2017 - europepmc.org
Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …
[HTML][HTML] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
LJ Rupp, K Schumann, KT Roybal, RE Gate, CJ Ye… - Scientific Reports, 2017 - nature.com
Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …
(including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both …